Drugs Stocks On The Rise With Help From 3 Stocks

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 38 points (0.2%) at 16,171 as of Friday, Feb. 21, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,939 issues advancing vs. 967 declining with 167 unchanged.

The Drugs industry currently sits up 1.2% versus the S&P 500, which is up 0.3%. Top gainers within the industry include Isis Pharmaceuticals ( ISIS), up 17.1%, Biogen Idec ( BIIB), up 3.9%, Regeneron Pharmaceuticals ( REGN), up 3.1%, Alexion Pharmaceuticals ( ALXN), up 1.9% and Amgen ( AMGN), up 1.2%. On the negative front, top decliners within the industry include Actavis ( ACT), down 1.7%, and Allergan ( AGN), down 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Johnson & Johnson ( JNJ) is one of the companies pushing the Drugs industry higher today. As of noon trading, Johnson & Johnson is up $0.48 (0.5%) to $92.20 on light volume. Thus far, 2.8 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 8.2 million shares. The stock has ranged in price between $91.46-$92.24 after having opened the day at $91.86 as compared to the previous trading day's close of $91.72.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $258.6 billion and is part of the health care sector. Shares are up 0.1% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Pfizer ( PFE) is up $0.18 (0.6%) to $31.74 on light volume. Thus far, 7.9 million shares of Pfizer exchanged hands as compared to its average daily volume of 25.9 million shares. The stock has ranged in price between $31.57-$31.77 after having opened the day at $31.64 as compared to the previous trading day's close of $31.55.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $204.0 billion and is part of the health care sector. Shares are up 3.0% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $0.57 (0.7%) to $83.38 on average volume. Thus far, 5.4 million shares of Gilead exchanged hands as compared to its average daily volume of 11.6 million shares. The stock has ranged in price between $82.94-$83.62 after having opened the day at $83.54 as compared to the previous trading day's close of $82.81.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $126.8 billion and is part of the health care sector. Shares are up 10.3% year-to-date as of the close of trading on Thursday. Currently there are 18 analysts who rate Gilead a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, increase in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?